此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

将比值转化为预后:中性粒细胞-淋巴细胞比值和血小板-淋巴细胞比值作为儿童烧伤患者ARDS的有力预测因子:一项前瞻性评估

2026年9月30日 更新者:Ain Shams University

将比值转化为预后:中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值作为儿科烧伤患者ARDS的强有力预测指标:一项前瞻性评估

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.

研究概览

详细说明

The aim of this study is to evaluate the role of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as predictors for development of ARDS in pediatric burn patients.

  • A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/authorized representatives of the patients.
  • All eligible pediatric patients with severe burns will be enrolled within 24 hours of admission after obtaining informed consent.
  • Minimum sample needed for statistical significance was calculated a priori and found to be (60).
  • After consent, Patients' characteristics (age, sex, etc….), clinical parameters (TBSA, Abbreviated Burn Severity Index [ABSI], presence of inhalational injury), and comorbidities will be recorded.
  • Complete blood count (CBC) will be done upon admission and will be repeated on days 1, 3, 5 and 7.
  • Total leucocyte count (TLC), differential leucocyte count (DLC) and platelet count (PC) will be reported as part of the CBC results. NLR and PLR will be calculated as per the following: NLR: ratio of absolute neutrophil count to absolute lymphocyte count. PLR: ratio of platelet counts to absolute lymphocyte count.
  • Data about respiratory status at ICU admission (invasive or non-invasive mechanical ventilation, high-flow oxygen therapy) and progression to endotracheal intubation and invasive mechanical ventilation (IMV), the day of endotracheal intubation and IMV initiation, and duration of ventilation will be recorded.
  • Patients will be evaluated on days 0,1, 3, 5, 7 of admission for diagnosis of ARDS.
  • ARDS will be determined using the pediatric ARDS criteria from the Pediatric Acute Lung Injury Consensus Conference.

Primary outcome:

o To evaluate the predictive value of admission NLR and PLR for development of ARDS within 30 days in pediatric burn patients.

Secondary outcomes:

  • Determine optimal cut-off values (ROC) of NLR and PLR for ARDS prediction.
  • Compare predictive performance of NLR and PLR with established clinical predictors (TBSA%, inhalation injury, age).
  • Study the predictive value of the dynamic changes of NLR/PLR for mechanical ventilation need, ventilator days, ICU length of stay, and mortality.

研究类型

观察性的

注册 (实际的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Cairo、埃及
        • Ain Shams University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 12年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

A prospective observational cohort study will be performed in our burn ICU at Ain Shams University Hospitals. Ethical clearance will be taken from the institutional ethics committee. Written informed consent will be obtained from the patients/authorized representatives of the patients.

All eligible pediatric patients with severe burns will be enrolled within 24 hours of admission after obtaining informed consent.

Minimum sample needed for statistical significance was calculated a priori and found to be (60).

After consent, Patients' characteristics (age, sex, etc….), clinical parameters (TBSA, Abbreviated Burn Severity Index [ABSI], presence of inhalational injury), and comorbidities will be recorded.

Patients will be evaluated on days 0,1, 3, 5, 7 of admission for diagnosis of ARDS.

ARDS will be determined using the pediatric ARDS criteria from the Pediatric Acute Lung Injury Consensus Conference .

描述

Inclusion Criteria:

  • Age 1-12 years.
  • Patients presenting within 24 hours of burn injury.
  • Patients presenting with severe burns 20-40% of total body surface area (TBSA).
  • Thermal burns or scalds.
  • Both sexes.

Exclusion Criteria:

  • Patient refusal to participate in the trial.
  • Age <1 & >12 years.
  • Delayed admission >24h post-injury.
  • Patients presenting with burns <20% or >40% of TBSA.
  • Non-thermal burns.
  • Associated medical comorbidities: Chronic liver or kidney diseases, anemia.
  • Preexisting chronic lung disease (e.g., cystic fibrosis, severe bronchopulmonary dysplasia).
  • Inflammatory conditions (e.g., inflammatory bowel disease).
  • Immunocompromised individuals, autoimmune diseases, those undergoing treatment with immunosuppressants, corticosteroids, cytotoxic chemotherapy.
  • Known malignancies, hematologic malignancy or conditions altering WBC/platelets significantly.
  • Previous malnutrition.
  • Immunosuppressive therapy prior to admission (e.g., chronic steroids).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction using the Pediatric Index of Mortality 2 score (PIM2 score).
大体时间:Within 30 days

the predictive value of admission Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction within 30 days in 60 pediatric burn patients using the Pediatric Index of Mortality 2 score (PIM2 score). The PIM2 score outputs a probability of death between 0% and 100%, the higher the score, the higher the motality risk. Low risk: <5-10% predicted mortality; Moderate risk: 10-20%; High risk: >20%

Within 30 days

次要结果测量

结果测量
措施说明
大体时间
optimal cut-off values
大体时间:30 days

optimal cut-off values (Receiver Operating Characteristic curve "ROC") of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for acute respiratory distress syndrome (ARDS) prediction in 60 pediatric burn patients.

30 days
comparison between Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) in clinical aspects using pediatric risk of mortality score (PRISM III score)
大体时间:30 days

Compare predictive performance of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) with established clinical predictors (Total Body Surface Area Percentage "TBSA%", inhalation injury, age in years) in 60 pediatric burn patients using pediatric risk of mortality score (PRISM III score). PRISM III Score Ranges from 0 to >25. 0-5 means Low risk of mortality, mild critical illness; 6-15 means Moderate risk; significant physiologic instability; 16-25 means High risk; severe multi-organ involvement; >25 means Extremely high risk; very critical state.

30 days
Dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) using the Pediatric Logistic Organ Dysfunction (PELOD) score to assess severity of burn.
大体时间:30 days

Study the predictive value of the dynamic changes of Neutrophil to Lymphocyte ratio (NLR) and Platelet to Lymphocyte ratio (PLR) for mechanical ventilation need, ventilator days, ICU length of stay in days, and mortality in 60 pediatric burn patients using the Pediatric Logistic Organ Dysfunction (PELOD) score. Maximum score: 33. Higher scores indicate greater severity. Higher PELOD-2 scores and involvement of multiple organ systems correlate with increased risk of mortality. A score >10 or involvement of >2 organs indicates significantly elevated risk.

30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月10日

初级完成 (实际的)

2026年9月10日

研究完成 (实际的)

2026年9月10日

研究注册日期

首次提交

2026年1月24日

首先提交符合 QC 标准的

2026年2月12日

首次发布 (实际的)

2026年2月17日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年2月1日

更多信息

与本研究相关的术语

其他研究编号

  • FMASU MD313/2025

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅